World Market Intelligence's 'Celgene Corporation (CELG) : Company Profile and SWOT Analysis' contains in depth information and data about the company and its operations. The profile contains a company overview, business description, financial ratios, SWOT analysis, competitive benchmarking, key facts, key employees, location and subsidiaries as well as information on products and services.
This SWOT analysis and company profile is a crucial resource for industry executives and anyone looking to gain a better understanding of the company's business.
WMI's 'Celgene Corporation (CELG) : Company Profile and SWOT Analysis' report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format.
WMI strictly follows a standardized research methodology to ensure high levels of data quality and these characteristics guarantee a unique report.
Examines and identifies key information and issues about 'Celgene Corporation' for business intelligence requirements
Studies and presents the company's strengths, weaknesses, opportunities (growth potential) and threats (competition). Strategic and operational business information is objectively reported
Provides analysis on financial ratios along with a competitor benchmarking section
The profile also contains information on business operations, company history, major products and services, key employees
Reasons To Buy
Quickly enhance your understanding of the company
Gain insight into the marketplace and a better understanding of internal and external factors which could impact the industry
Recognize potential partnerships and suppliers
Obtain yearly profitability figures
Celgene Corporation (Celgene) is an integrated biopharmaceutical company. The company primarily focuses on the research, development, manufacture, and marketing of therapies for the treatment of cancer and immune-inflammatory-related diseases. The company has five marketed products, REVLIMID, THALOMID and VIDAZA, ABRAXANE, and ISTODAX. The company also conducts Investigational compound studies for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, and chronic lymphocyte leukemia (CLL). The company's operations are spread across more than 65 countries and regions, including Europe, Latin America, Middle East, Asia-Pacific and Canada. It operates outside the US, through its subsidiaries and distributors. Celgene is headquartered in Summit (New Jersey), the US.